The NETO2 Knockout Raji Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Raji B lymphocyte line. This product provides a loss-of-function model for NETO2, generated via CRISPR/Cas9-mediated gene disruption in a bulk cell pool, yielding a heterogeneous population with diverse editing events. The polyclonal format avoids clonal bias and is suitable for transient and stable functional assays in immunology and cancer research.
The Raji cell line is a well-established model of human Burkitt lymphoma, originating from an 11-year-old male. These lymphoblastoid cells are EBV-positive and express B cell markers (CD19, CD20, CD10) but lack surface immunoglobulin. Raji cells are extensively used to investigate EBV-driven lymphomagenesis, B cell signaling, and lymphoma biology, offering a robust platform for gene function studies in a malignant lymphocyte context.
NETO2 is a single-pass transmembrane protein that serves as an auxiliary subunit of kainate-type ionotropic glutamate receptors, including GRIK1?CGRIK5. It directly binds these subunits and modulates their surface expression and desensitization kinetics, fine-tuning glutamatergic neurotransmission. NETO2 also interacts with C1q-like proteins, NETO1, and the postsynaptic scaffold PSD-95 (Dlg4). Downstream, it influences calcium/calmodulin-dependent kinase II (CaMKII) and the MAPK/ERK pathway. Although well-studied in neurons, NETO2??s function in B cells is largely unknown.
Knocking out NETO2 in Raji cells creates a powerful tool to probe its potential roles in B lymphocyte biology and EBV-related pathologies. As Raji cells express an EBV latency program and are derived from Burkitt lymphoma, this model allows assessment of whether NETO2 contributes to B cell receptor-like signaling, viral latency maintenance, or lymphoma cell survival. Given emerging evidence of glutamate receptor expression in immune cells, this system enables hypothesis-driven exploration of NETO2-dependent pathways in lymphomagenesis.
These polyclonal knockout cells support a wide range of experimental applications. Researchers can quantify NETO2 mRNA and protein via RT-qPCR and Western blotting, detect surface NETO2 by flow cytometry, and measure intracellular calcium fluxes with ion imaging. Functional assays for proliferation (MTT), apoptosis (Annexin V), and migration (Transwell) can dissect NETO2??s impact on cell behavior. Furthermore, co-immunoprecipitation and RNA-seq are ideal for mapping the NETO2 interactome and transcriptome in B cells. The cells are also valuable for drug screening targeting NETO2-related pathways in lymphoma. For detailed protocols, validation data, or custom applications, please contact Ascent Research.
